AIDS 2016: Second Durban Declaration Highlights Key Advances and Barriers

In advance of the 21st International AIDS Conference (AIDS 2016), starting July 18 in Durban, South Africa, the International AIDS Society has released the Second Durban Declaration, highlighting the 5 key scientific advances in the HIV field and 5 key structural barriers that have yet to be overcome.


ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.


ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.


Coverage of ASM Microbe 2016 (ICAAC 2016) coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.

Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.

Full coverage listing by topic

ASM Microbe 2016 website



New California Grants Address Disparities in HIV Prevention and Care

An $9 million effort funded by the California HIV/AIDS Research Program (CHRP) will create new interventions tailored to reach heard-to-reach and heavily impacted groups living with or at risk for HIV, including homeless youth, HIV-positive young men of color, young people who use drugs or alcohol, the House Ball community, and women with barriers to care. The new initiative aims to increase HIV testing, treatment initiation, adherence to therapy, and retention in HIV care.


ASM Microbe 2016: HIV Seroconversion Is Rare If PrEP Is Used Consistently

New HIV infections occurred at a low rate of about 1 per 100 person-years among people who took Truvada for pre-exposure prophylaxis (PrEP), with seroconversions mostly seen in those who stopped taking their pills, according to an analysis of more than 30 studies and demonstration projects presented last week at the ASM Microbe 2016 conference in Boston.


Less Frequent CD4 and Viral Load Monitoring Safe for People Doing Well on ART

The frequency of routine monitoring for people treated with antiretrovirals who have viral suppression can be safely reduced from every 3 months to every 6 months, investigators from Europe and the U.S. reported in the June 1 edition of the Journal of Acquired Immune Deficiency Syndromes. However, people followed-up every 9 to 12 months were more likely to experience virological failure and also had lower CD4 cell increases compared to people monitored every 3 months.